A Common Antidepressant May Give Cancer Patients a Powerful Survival Edge

A Surprising Link Between Mental Health Drugs and Cancer Outcomes

People undergoing cancer treatment often experience depression or anxiety, taking medication for their mental health alongside drugs aimed at their tumors. Researchers are now investigating an unexpected connection between those treatments. What they found could reshape how oncologists think about the medications their patients are already taking.

A new analysis found that patients taking common antidepressants had fewer deaths recorded over two years after beginning immunotherapy, a treatment that helps the immune system attack cancer. According to the study, published in PLOS Medicine, the use of SSRI-class antidepressants may reduce the two-year mortality risk by 37% in patients undergoing cancer immunotherapy.

What the Research Actually Found

Led by physician Po-Huang Chen of Tri-Service General Hospital and National Defense Medical University, the research identified eligible patients through the TriNetX electronic health record network who began immunotherapy between 2015 and 2025. In the study, 1,567 SSRI users were matched with 1,567 people taking benzodiazepines — medications prescribed for anxiety and insomnia — with matching covering 49 baseline characteristics, including demographics, tumor characteristics, other illnesses, medications, and laboratory results.

Analysis of the data revealed that during a two-year follow-up period, 368 deaths occurred in the SSRI group compared to 539 deaths in the benzodiazepine group — a mortality rate of 23.5% versus 34.4%. SSRIs, short for selective serotonin reuptake inhibitors, block the reuptake of serotonin, a chemical messenger. The group includes fluoxetine, sertraline, and escitalopram. These are among the most widely prescribed drugs in the world.

The Biology Behind the Benefit

The serotonin transporter protein located on T cells — the immune cells that attack cancer — acts as a braking mechanism that limits their function. SSRI drugs appear to increase the capacity of immune cells to fight tumors by blocking this protein. As oncologist Cho-Hao Lee of Tri-Service General Hospital put it, "The simplest way to put it is that SSRIs may release a second brake on immunity that sits right next to the one checkpoint inhibitors release."

The team separately analyzed 8,272 tumor samples from The Cancer Genome Atlas. Across 13 of 20 cancer types, higher expression of the gene encoding the serotonin transporter correlated with lower scores for T-cell inflammation — suggesting that when serotonin transport is suppressed, immune cells may be freer to do their job. The findings support the proposed mechanism, though whether antidepressant doses alter serotonin levels or T-cell behavior within patients' tumors remains unknown.

What This Means — and What It Doesn't

The study also noted a difference in thyroid problems: thyroid dysfunction was recorded in 31.6% of SSRI users, compared with 26.7% of benzodiazepine users, while rates of hepatitis, pneumonitis, and colitis did not differ significantly. Researchers are still working to understand what that gap means for patients long-term.

For patients, Lee's message is clear: "This is not a reason to start an SSRI to 'boost' immunotherapy, or to stop a benzodiazepine on your own." This is observational data, not a clinical trial, and causation hasn't been proven. Still, the findings open a compelling new door. Millions of cancer patients are already taking SSRIs for mental health reasons — if further research confirms the survival benefit, these everyday medications could become an important and low-cost piece of the cancer treatment puzzle.